Trial Profile
A Multi-Center Open-Label Phase I/2 Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Oct 2021
Price :
$35
*
At a glance
- Drugs Bemcentinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors BerGenBio
- 08 Jun 2021 Status changed from recruiting to completed, as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jun 2021 Results (data cut off date- 7 Oct 2020) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 22 Oct 2018 Results published in a BerGenBio media release.